Providence Medical touts 2-year cervical fusion data, $2.9m funding round

Cervical spine-focused Providence Medical last week released 2-year radiographic and clinical outcomes from a study of its DTrax system of instruments and implants and announced a $2.8 million round of equity financing. Results from the single-arm, multi-center study were presented at the Spine Week 2016 conference in Singapore last week, the Walnut Creek, Calif.-based company said. “The 2-year results of this study are promising and suggest DTrax technology is a valuable addition to the armamentarium of options for surgeons treating patients with cervical radiculopathy,” Dr. Kris Siemionow of Chicago’s University of Illinois said in a press release. Data from the study of 53 patients who underwent posterior cervical fusion for spondylotic radiculopathy using the DTrax suite of devices indicated significant reductions on the Neck Disability index, VAS Neck Pain and Arm Pain scores and SF-12 MCS scores. No significant changes in overall or segmental lordosis after surgery were recorded, and the company reported a radiographic fusion rate of 98.1%. No device failures, implant lucency or surgical re-interventions were reported, the company said. “Providence has been committed to providing clinical evidence since the company’s inception. We are encouraged by this evidence supporting the safety and efficacy of decompression and stabilization with DTrax technology for the treatment of cervical radiculopathy. We believe that DTrax technology fills critica...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Clinical Trials Spinal Surgical Providence Medical Technology Source Type: news